Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Akebia Therapeutics (AKBA) Change in Account Payables: 2013-2024

Historic Change in Account Payables for Akebia Therapeutics (AKBA) over the last 12 years, with Dec 2024 value amounting to -$1.4 million.

  • Akebia Therapeutics' Change in Account Payables fell 191.16% to -$8.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$4.9 million, marking a year-over-year decrease of 763.49%. This contributed to the annual value of -$1.4 million for FY2024, which is 73.99% up from last year.
  • Latest data reveals that Akebia Therapeutics reported Change in Account Payables of -$1.4 million as of FY2024, which was up 73.99% from -$5.2 million recorded in FY2023.
  • In the past 5 years, Akebia Therapeutics' Change in Account Payables registered a high of $3.7 million during FY2020, and its lowest value of -$11.7 million during FY2021.
  • Its 3-year average for Change in Account Payables is -$1.7 million, with a median of -$1.4 million in 2024.
  • In the last 5 years, Akebia Therapeutics' Change in Account Payables surged by 168.08% in 2020 and then plummeted by 449.37% in 2023.
  • Over the past 5 years, Akebia Therapeutics' Change in Account Payables (Yearly) stood at $3.7 million in 2020, then tumbled by 419.06% to -$11.7 million in 2021, then spiked by 112.79% to $1.5 million in 2022, then plummeted by 449.37% to -$5.2 million in 2023, then skyrocketed by 73.99% to -$1.4 million in 2024.